6 studies found for:    weill | Open Studies | "Pancreatic Neoplasms"
Show Display Options
Rank Status Study
1 Recruiting EUS-Guided ERCP Multicenter Registry
Conditions: Cholangiocarcinoma;   Pancreatic Cancer;   Bile Duct Cancer;   Biliary Stricture;   Biliary Obstruction;   Stent Obstruction;   Proximal Duct Stricture;   Distal Duct Stricture;   Ampullary Cancer;   Biliary Sphincter Stenosis;   Impacted Stones;   Chronic Pancreatitis;   Peri-ampullary Diverticula;   Altered Anatomy
Intervention: Procedure: EUS guided ERCP
2 Recruiting Radio Frequency Ablation in the Management of Pancreatico-biliary Disorders: A Multicenter Registry
Conditions: Cholangiocarcinoma;   Pancreatic Cancer;   Bile Duct Cancer;   Biliary Stricture;   Bile Duct Obstruction
Intervention: Device: Radio Frequency ablation Probe
3 Recruiting Interventional Endoscopy Database for Pancreatico-biliary, Gastrointestinal and Esophageal Disorders
Conditions: Ampullary Cancer;   Duodenal Cancer;   Bile Duct Cancer;   Bile Duct Disorders;   Gallstones;   Obstructive Jaundice;   Pancreatic Disorders (Noncancerous);   Colorectal Cancer;   Esophageal Cancer;   Barrett's Esophagus;   Gastric Malignancies;   Pancreatic Cancer;   Pediatric Gastroenterology;   Cholangiocarcinoma;   Pancreatic Pseudocysts;   Acute and Chronic Pancreatitis;   Recurrent Pancreatitis;   Cholangitis;   Bile Leak;   Biliary Strictures;   Pancreatic Divisum;   Biliary and Pancreatic Stones;   Choledocholithiasis
Intervention:
4 Unknown  177Lu-J591 Antibody in Patients With Nonprostate Metastatic Solid Tumors
Conditions: Kidney Cancer;   Head and Neck Cancer;   Breast Cancer;   Non-small Cell Lung Cancer;   Colorectal Cancer;   Pancreatic Cancer;   Ovarian Cancer;   Esophageal Cancer;   Gliomas
Intervention: Drug: 177Lu-J591
5 Recruiting RFA RCT for Pancreatic or Bile Duct Cancer
Conditions: Unresectable Pancreatic Cancer;   Cholangiocarcinoma Non-resectable
Interventions: Procedure: Radiofrequency Ablation using EndoHPB Probe;   Procedure: Stenting only
6 Recruiting Phase 3 Trial of 90Y-Clivatuzumab Tetraxetan & Gemcitabine vs Placebo & Gemcitabine in Metastatic Pancreatic Cancer
Conditions: Metastatic Pancreatic Cancer;   Pancreatic Cancer
Interventions: Drug: IMMU-107;   Drug: placebo;   Drug: Gemcitabine

Indicates status has not been verified in more than two years